VIVO Cannabis (TM) Announces Launch of Beacon Medical (TM) High Dose CBD Oil and Pediatric Compassionate Care Program


Step onto Wall Street with StreetInsider Premium. Request your one-week free trial here.

Toronto, Ontario – (Newsfile Corp. – November 23, 2021) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Company”), a leading provider of medical cannabis products and patient services and licensed under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc., today announced the launch of its latest medical cannabis product formulation: High Dose Cannabidiol (CBD) Oil under the Beacon Medical brand. “

Beacon Medical “2: 100 High Dose CBD Oil is a distillate-based cannabis oil that contains 100 mg of CBD and less than 2 mg of tetrahydrocannabinol (THC). The entire Beacon Medical” family of oil products is formulated using a GMO-free food made from carrier oil medium-chain triglycerides (MCT) of the grade, making the end product both odorless and tasteless.

“With our commitment to the medical cannabis market, the VIVO team strives to offer our patients first-class cannabinoid-based medical products and the Beacon Medical” CBD + | O was launched in response to the patient insights our team has gained over time, “commented Ray Laflamme, Co-Founder of Canna Farms and CEO of VIVO.” We know that many of our patients are looking for products that meet their individual needs and this latest addition to Beacon Medical’s family of products is an excellent high potency CBD option for patients and will be available to patients, doctors and hospitals alike. ”

Beacon CBD + | O [2:100] Extra strong CBD oil to help patients meet their health goals

To view an improved version of this graphic, please visit:

VIVO also announced the launch of a Pediatric Compassionate Care program to support caregivers and families in need of medicinal cannabis for the treatment of a wide variety of pediatric conditions. Eligible patients receive significant discounts on all CBD products from Beacon Medical, “Canna Farms,” ​​Fireside, “and Lumina”.

VIVO stands for its patient-centered approach that ensures choice, access and consistent care for patients. Beacon Medical “products are only available in select medical markets in Canada, Australia and Germany.

This newly launched CBD oil from Beacon Medical is available to Canadian medical customers through Canna Farms’ medical e-commerce marketplace. Patients who require assistance with registration or ordering can contact the VIVO customer service team at 1 (855) 882-0988 or care @.

About VIVO Cannabis ”

VIVO Cannabis “is known for trusted, world-class cannabis products and services. It holds manufacturing and distribution licenses from Health Canada and operates world-class indoor and seasonal airhouse grow facilities. VIVO has a collection of medical, health and wellness brands that each across customer segments including Canna Farms, “Beacon Medical,” Fireside, “and Lumina”. Harvest Medicine, “VIVO’s patient-centric, scalable network of medical cannabis clinics, has served over 150,000 patient visits. VIVO pursues several partnership and product development opportunities and focuses its international efforts on Germany and Australia. Further information is available at:

For more information:

VIVO Investor Relations
+1 416-848-9839


Disclaimer for forward-looking information

Certain statements in this press release are forward-looking statements that are not purely historical, including statements regarding the beliefs, plans, expectations, or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that could mean that the actual results, performance or developments differ materially from those contained in the forward-looking statements. There can be no assurance that any of the events anticipated in the forward-looking statements will occur or what the Company will benefit from. Readers are urged to carefully consider these factors, along with the wider risk factors contained in the company’s recent discussion and analysis on SEDAR, in evaluating the forward-looking statements in this press release, and not place undue reliance on such forward-looking statements Statements that are restricted in their entirety by these warning notices. The forward-looking statements in this press release are made as of the date of this press release and the company disclaims any intention or obligation to publicly update such forward-looking statements, whether as a result of new information, future events or results or otherwise, unless otherwise Securities laws required by applicable law.

To view the source version of this press release, please visit